Mechanism of Demyelinating Diseases of the Central Nervous System: A Therapeutic Approach with Anticoagulants

1947 ◽  
Vol 14 (3) ◽  
pp. 153-158
Author(s):  
H. KAMMER ◽  
L. J. KARNOSH
2000 ◽  
Vol 107 (2) ◽  
pp. 184-190 ◽  
Author(s):  
Gianvito Martino ◽  
Pietro L Poliani ◽  
Roberto Furlan ◽  
Peggy Marconi ◽  
Joseph C Glorioso ◽  
...  

2021 ◽  
Vol 50 ◽  
pp. 102800
Author(s):  
Maryam Sharifian-Dorche ◽  
Mohammad Ali Sahraian ◽  
Giulia Fadda ◽  
Michael Osherov ◽  
Amirhossein Sharifian-Dorche ◽  
...  

2021 ◽  
Author(s):  
Luiza Kohler Seixas ◽  
Marcio da Silva Paz ◽  
Claudia Suemi Kamoi Kay ◽  
Lineu Cesar Werneck ◽  
Paulo José Lorenzoni ◽  
...  

Background: The most prevalent autoimmune diseases (AID) of the Central Nervous System (CNS) are Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD), both being demyelinating diseases. Recent studies show that patients with CNS demyelinating diseases have a higher risk of presenting associated diagnosis of another AIDs. Objectives: The present study aimed to evaluate the frequency of autoimmune comorbidities and autoantibodies in patients with MS and NMOSD. Design and setting: Were analyzed the medical records of 126 patients with MS or NMOSD, from the Demyelinating Diseases Outpatient Clinic in the Neurological and Psychiatric Unit in the Complexo Hospital de Clinicas da Universidade Federal do Parana (CHC-UFPR), taking in consideration the presence of AIDs and autoantibodies. Methods: The variables were organized in a Microsoft® Office Excel spreadsheet for statistical analysis. Results: Of the 126 analyzed cases, 111 (88%) corresponded to MS and 15 (12%) to NMOSD. From the total, at least one AID was associated in 11 patients (8.7%), six of which were diagnosed with MS and five with NMOSD (p<0.05). Regarding autoantibodies, there were 21 cases (16.7%) in which antinuclear antibodies (ANA) were present, and 12 cases (9.5%) in which autoantibodies other than ANA were present (p<0.05). Conclusions: The results of the study showed a higher frequency of AIDs in patients with CNS demyelinating diseases compared to the normal population. The results found in this study may contribute to improve the treatment and follow-up of patients with CNS demyelinating diseases, so that the concomitance of other AIDs is considered by the clinician.


Author(s):  
Konstantin Gulyabin

Mills' syndrome is a rare neurological disorder. Its nosological nature is currently not completely determined. Nevertheless, Mills' syndrome is considered to be a rare variant of the degenerative pathology of the central nervous system – a variant of focal cortical atrophy. The true prevalence of this pathology is unknown, since this condition is more often of a syndrome type, observed in the clinical picture of a number of neurological diseases (primary lateral sclerosis, frontotemporal dementia, etc.) and is less common in isolated form.


2021 ◽  
pp. 106689692199356
Author(s):  
Fleur Cordier ◽  
Lars Velthof ◽  
David Creytens ◽  
Jo Van Dorpe

Acute disseminated encephalomyelitis (ADEM) is a rare immune-mediated inflammatory and demyelinating disorder of the central nervous system. Its characteristic perivenular demyelination and inflammation aid in the differential diagnosis with other inflammatory demyelinating diseases. Here, we present a clinical case of ADEM, summarize its histological hallmarks, and discuss pitfalls concerning the most important neuropathological differential diagnoses.


Sign in / Sign up

Export Citation Format

Share Document